Health technologies have the potential to save millions of lives. New tools are needed to slow the global threat of diseases, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases, and tackle many other pressing health needs. For diseases and conditions primarily affecting people in the world’s poorest places, there is little to no commercial market to spur R&D. Strong investment and innovative solutions are needed to catalyze the development of new technologies to bring health and opportunity in reach for all people.
GHTC issued a statement at the 140th session of the World Health Organization (WHO) Executive Board welcoming progress by WHO in operationalizing a Global Observatory on Health Research and Development as a follow-up to the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG). The statement, which was issued in partnership with the Global Health Council, also encouraged member states to fully fund the observatory and recommended diverse global health stakeholders be consulted as the process moves forward.
GHTC issued a statement at the 140th session of the World Health Organization (WHO) Executive Board supporting the assembly’s resolution on antimicrobial resistance (AMR), which incorporates R&D as a vital part of WHO’s strategy to combat AMR. The statement also calls for WHO to accelerate efforts to develop accountability frameworks to ensure AMR commitments are realized. The statement was issued in partnership with the Global Health Council and PATH.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
The 140th session of the World Health Organization (WHO) Executive Board (EB) closed last week with a shortlist of three candidates for the WHO Director General position and progress on key global health R&D issues.